Xcout Intel
Vaximm
VAXIMM AG is a biotech company headquartered in Basel, Switzerland, that focuses on developing a new class of cytotoxic immunotherapies and clinical-stage targeted treatments through its subsidiaries.
Subscribe to see Vaximm’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Vaximm at a glance
Vaximm is a biotechnology company headquartered in Germany, founded in 2008. Its most recent funding round, Series A, raised $8.3M in January 2011. Xcout tracks 2 named people at Vaximm, including Andreas Niethammer (Chief Executive Officer).
Vaximm leadership
- Andreas NiethammerChief Executive Officer
- Sébastien WieckowskiChief Scientific Officer
Vaximm funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $8.3M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Vaximm competitors
A few of Vaximm's closest competitors — see the full list of competitors and alternatives →
Vaderis Therapeutics AG is a clinical-stage biotechnology company focused on developing novel treatments for severe vascular diseases. The company is headquartered in Basel, Switzerland.
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]
TECregen AG is a biotechnology company headquartered in Basel, Switzerland. The company is dedicated to advancing immuno-rejuvenation through the development of next-generation therapies designed to regenerate the thymus.
Anaveon is a late-stage preclinical biotechnology company based in Basel, Switzerland, focused on developing engineered antibodies for immunotherapy.
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Get Vaximm's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Vaximm in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access